Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications


Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Department of Gastroenterology and Hepatology, Kinki University Faculty of Medicine, Osaka-Sayama, Department of Gastroenterology and Metabolology, Ehime University Graduate School of Medicine, Ehime, Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Department of Gastroenterology, Asahi General Hospital, Asahi, Department of Gastroenterology, Okayama City Hospital, Okayama, Department of Gastroenterology, Saiseikai Niigata Daini Hospital, Niigata, Department of Gastroenterology, Toyama University Hospital, Toyama, and Hepato-Biliary Center, Matsuyama Red Cross Hospital, Matsuyama, Japan

Keywords
ALBI grade · Indocyanine green · Liver damage · Child-Pugh · Hepatocellular carcinoma

Abstract
Aim/Background: The purpose of this study was to evaluate the validity of 3 classifications for assessing liver function, the liver damage and Child-Pugh classifications and the newly proposed albumin-bilirubin (ALBI) grade, in order to examine the feasibility of evaluating hepatic function using ALBI grade with the hepatocellular carcinoma (HCC) treatment algorithm used in Japan. Methods: We analyzed the medical records of 3,495 Japanese HCC patients

See related article by Kudo: Albumin-Bilirubin Grade and Hepatocellular Carcinoma Treatment Algorithm. DOI 10.1159/000462199, published on pp. 185-188.
admitted from 2000 to 2015, which were comprised of 1,580 patients hospitalized in the Ehime Prefecture area and used as a training cohort (Ehime group), and 1,915 others who were used for validation (validation group). ALBI score used for grading \( \leq -2.60 = \text{grade 1}, \text{greater than } -2.60 \text{ to } \leq -1.39 = \text{grade 2}, \text{greater than } -1.39 = \text{grade 3} \) as well as clinical features and prognosis (Japan Integrated Staging [JIS], modified JIS, ALBI-TNM [ALBI-T] score) were retrospectively investigated. **Results:** For prediction of liver damage A, the values for sensitivity and specificity, positive predictive and negative predictive values, and positive and negative likelihood ratios of ALBI-1 and Child-Pugh A were similar among the 2 groups. Akaike information criterion results showed that prognosis based on ALBI grade/ALBI-T score was better than that based on liver damage/modified JIS score and Child-Pugh/JIS score (22,291.8/21,989.4, 22,379.6/22,076.0, 22,392.1/22,075.1, respectively). The cutoff values for ALBI score for indocyanine green retention rate at 15 min (ICG-R15) <10, <20, and <30% were –2.623 (area under the curve [AUC]: 0.798), –2.470 (AUC: 0.791), and –2.222 (AUC: 0.843), respectively. The distribution of ICG-R15 (<10%, 10 to <20%, 20 to <30%, and ≥30%) for ALBI grade 1 was similar to that for liver damage A. There were only small differences with regard to therapeutic selection with the Japanese HCC treatment algorithm between liver damage and ALBI grade. **Conclusion:** ALBI grade is a useful and easy classification system for assessment of hepatic function for therapeutic decision making.

**Introduction**

In Japan, the degree of liver damage as a guide to liver function (liver damage classification) [1] has been defined based on ascites, serum bilirubin, serum albumin, indocyanine green retention rate at 15 min (ICG-R15) (%), and prothrombin time activity (%) by the Liver Cancer Study Group of Japan (LCSGJ) (Table 1). The liver damage classification is utilized for evaluation of hepatic function with the hepatocellular carcinoma (HCC) treatment algorithm of the evidence-based Japan Society of Hepatology (JSH) guideline [2, 3]. Moreover, ICG-R15 has been reported to be a useful marker for predicting the hepatic function of a safely resectable segment in patients with HCC [4–6]. However, ICG-R15 data are not easily obtained in all patients, because ICG injection is needed. On the other hand, the Child-Pugh classification [7] is used worldwide for evaluation of hepatic function in patients with liver cirrhosis. As for the weak points of the Child-Pugh classification, some factors are subjective (ascites, encephalopathy), while interrelated factors (serum albumin, ascites) also exist. Omagari et al. [8] reported that the liver damage classification is a more effective evaluation method for patients with early stage HCC as compared to the Child-Pugh classification. Recently, a simple evaluation method for hepatic function, termed albumin-bilirubin (ALBI) grade, which is calculated using only serum albumin and total bilirubin, has been proposed [9], and some have reported its usefulness for HCC treatment planning [9–16].

ALBI grade [13] and liver damage [8] have been reported to have better capability for evaluation of hepatic function in Japanese HCC patients as compared to the Child-Pugh classification, though few studies have assessed the correlation between them. In the present study, we investigated the clinical usefulness of the ALBI grade by comparing it with both the liver damage and Child-Pugh classifications to analyze whether the ALBI grade can be substituted for the liver damage classification in the evidence-based JSH guideline.
Materials and Methods

Patients
From 2000 to 2015, 3,495 patients with naive HCC were examined using ICG-R15 at 9 different institutions (Ehime Prefectural Hospital \( n = 940 \), Ehime University Hospital \( n = 268 \), Matsuyama Red Cross Hospital \( n = 372 \), Ogaki Municipal Hospital \( n = 844 \), Okayama City Hospital \( n = 135 \), Teine Keijinkai Hospital \( n = 546 \), Asahi General Hospital \( n = 124 \), Saiakai Niigata Hospital \( n = 111 \), Toyama University Hospital \( n = 155 \)). After receiving informed consent, ICG-R15 was determined following a bolus injection of ICG (0.5 mg/kg) prior to therapy for HCC. ALBI score was calculated based on serum albumin and total bilirubin using the following formula, ALBI-score: \( \log_{10} \text{bilirubin} [\mu\text{mol/L}] \times 0.66 + (\text{albumin} [\text{g/L}] \times –0.085) \), while ALBI grade was defined by the resulting score (\( \leq –2.60 = \text{grade 1} \), greater than –2.60 to \( \leq –1.39 = \text{grade 2} \), greater than –1.39 = grade 3) [9].

Patients positive for anti-hepatitis C virus (HCV) were judged to have HCC due to HCV, and those positive for hepatitis B virus surface antigen (HBsAg) were judged to have HCC due to hepatitis B virus (HBV). Those without anti-HCV and HBsAg were defined as negative for both HBV and HCV (nonBnonC).

Comparison between Three Methods for Evaluation of Hepatic Function
We examined the relationship between the liver damage (Table 1) and Child-Pugh classifications and the ALBI grade using a validation cohort. Patients treated at institutions located in Ehime Prefecture (Ehime Prefectural Hospital, Ehime University Hospital, Matsuyama Red Cross Hospital) were defined as the training cohort \( n = 1,580 \), Ehime group), while the others were used as the validation cohort \( n = 1,915 \), validation group). For predicting liver damage class A, which often has good values of ICG-R15, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio, and negative likelihood ratio ratio of ALBI grade 1 and Child-Pugh class A were estimated in both groups.

The number of patients was investigated in each arm of the therapeutic option of the evidence-based JSH guideline [2, 3], with each grade used for assessment of hepatic function. In addition, we retrospectively evaluated the prognosis shown by each classification for hepatic function, and the prognosis shown by 3 different prognostic staging systems [Japan Integrated Staging (JIS) score, modified JIS score, ALBI-TNM (ALBI-T) score]. The distribution of ICG-R15 in each classification of hepatic function was investigated. JIS score was calculated using TNM stage of LCSGJ and Child-Pugh class [17, 18], modified JIS score using TNM stage of LCSGJ and liver damage [19], and ALBI-T using TNM stage of LCSGJ and ALBI grade [13].

Diagnosis and Surveillance of HCC Patients
HCC was diagnosed based on an increasing course of α-fetoprotein, as well as dynamic CT [20], magnetic resonance imaging, contrast-enhanced US with perflubutane (Sonazoid®, Daiichi Sankyo Co., Ltd., Tokyo, Japan) [21], and/or pathological findings. TNM stage was determined as reported in studies for staging of HCC conducted by the LCSGJ, ed 6 [1].

Treatment Criteria
After 2005, all treatments were performed following the Japanese practical guidelines for HCC [2, 3], whenever possible. All treatments were performed after obtaining written informed consent from the
patient. The study protocol was approved by the Institutional Ethics Committee of Ehime Prefectural Central Hospital (No. 28-30).

### Statistical Analysis

Data are expressed as median values or interquartile range (IQR). Statistical analyses were performed using the Student t test, Mann-Whitney U test, $\chi^2$ test, Pearson test, log-rank test, and Kaplan-Meier methods. A $p$ value <0.05 was considered to indicate statistical significance. Akaike information criterion (AIC) for prognosis with each method, receiver operating characteristic (ROC), and the area under the curve (AUC) were calculated for comparisons between the ALBI score and ICG-R15. All statistical analyses were performed using Easy R (EZR) (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [22], a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [23].

### Results

#### Clinical Backgrounds of Enrolled Patients

The total number of patients diagnosed with and/or treated for HCC from 2000 to 2015 at our institutions was 7,565, of whom 3,495 (46.2%; 2,488 males, 1,007 females; median age 70 years old, IQR 62–75 years) were enrolled in the present study. Their clinical backgrounds are shown in Table 2. HCV was the diagnosis in 2,257, HBV in 506, HBV and HCV in 18, and nonBnonC in 714 patients. In the comparisons between the Ehime and validation groups, there were significant differences with regard to gender, AST, ALT, platelets, total bilirubin, ascites, encephalopathy, ICG-R15, liver damage classification, Child-Pugh classification, ALBI grade, tumor number (single and multiple), α-fetoprotein ($\geq$100 ng/mL), des-γ-carboxy prothrombin, and therapies (Table 2).

Surgical resection was performed in 1,274 (36.5%) patients, radiofrequency ablation (RFA) [24, 25] in 1,652 (47.3%), percutaneous ethanol injection in 51 (1.5%), and transcatheter arterial chemoembolization in 462 (13.2%), while other treatments including supportive care were performed in 56 (1.6%).

Grade distribution for each of the 3 hepatic function assessment methods is shown in Table 3. In the Ehime group, the values for sensitivity, specificity, PPV, NPV, positive likelihood ratio, and negative likelihood ratio for predicting liver damage class A based on ALBI grade 1 were 0.677, 0.851, 0.831, 0.708, 4.534 (95% CI: 3.800–5.409), and 0.380 (95% CI: 0.343–0.421), respectively, while those based on Child-Pugh class A were 0.999, 0.413, 0.649, 0.997, 1.703 (95% CI: 1.604–1.808), and 0.003 (95% CI: 0.000–0.021), respectively. In the validation group, those values for predicting liver damage class A based on ALBI grade 1 were 0.632, 0.906, 0.908, 0.628, 6.739 (95% CI: 5.393–8.422), and 0.406 (95% CI: 0.375–0.439), respectively, and those based on Child-Pugh class A were 0.995, 0.438, 0.721, 0.983, 0.769, 1.771 (95% CI: 1.664–1.885), and 0.012 (95% CI: 0.005–0.027), respectively. Similar tendencies for these values were seen in both groups. For all 3,495 enrolled patients, the values for sensitivity, specificity, PPV, NPV, positive likelihood ratio, and negative likelihood ratio for predicting liver damage class A based on ALBI grade 1 were 0.651, 0.879, 0.873, 0.664, 0.751, 5.373 (95% CI: 4.677–6.171), and 0.397 (95% CI: 0.373–0.423), respectively, and those based on Child-Pugh class A were 0.996, 0.426, 0.689, 0.989, 0.746, 1.736 (95% CI: 1.663–1.813), and 0.008 (95% CI: 0.004–0.018), respectively.

When each grade was used for assessment of hepatic function with the evidence-based JSH guideline, after exclusion of patients with major vein invasion, extrhepatic metastasis, and/or rupture ($n = 209$), the numbers of patients in arms 1, 2, 3, 4, and 5 of the algorithm with the use of the liver damage classification were 2,138, 554, 257, 203, and 134, respectively, while the numbers of patients in those arms using the Child-Pugh classification were
### Table 2. Clinical backgrounds of patients and comparisons between the Ehime and validation groups

<table>
<thead>
<tr>
<th></th>
<th>Ehime group (n = 1,580)</th>
<th>Validation group (n = 1,915)</th>
<th>Total (n = 3,495)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years</strong></td>
<td>69 (62–76)</td>
<td>70 (63–75)</td>
<td>70 (62–75)</td>
</tr>
<tr>
<td><strong>Gender, male:female</strong></td>
<td>1,111:469</td>
<td>1,377:538</td>
<td>2,488:1,007</td>
</tr>
<tr>
<td><strong>AST, IU/L</strong></td>
<td>52 (36–76)</td>
<td>47 (33–67)**</td>
<td>50 (35–72)</td>
</tr>
<tr>
<td><strong>ALT, IU/L</strong></td>
<td>42 (27–66)</td>
<td>40 (26–63)*</td>
<td>41 (27–64)</td>
</tr>
<tr>
<td><strong>Platelets, x10⁴ cells/μL</strong></td>
<td>11.0 (7.8–15.4)</td>
<td>11.9 (8.4–16.4)**</td>
<td>11.4 (8.1–15.8)</td>
</tr>
<tr>
<td><strong>Total bilirubin, mg/dL</strong></td>
<td>0.8 (0.6–1.1)</td>
<td>0.7 (0.6–1.0)**</td>
<td>0.8 (0.6–1.0)</td>
</tr>
<tr>
<td><strong>Albumin, g/dL</strong></td>
<td>3.8 (3.4–4.2)</td>
<td>3.8 (3.5–4.1)</td>
<td>3.8 (3.4–4.1)</td>
</tr>
<tr>
<td><strong>Prothrombin time, %</strong></td>
<td>84.1 (73.2–95.5)</td>
<td>87.6 (75.0–96.7)</td>
<td>86.0 (74.0–96.0)</td>
</tr>
<tr>
<td><strong>Ascites, none:mild:moderate to severe</strong></td>
<td>1,442:104:34</td>
<td>1,822:86:7**</td>
<td>3,264:190:41</td>
</tr>
<tr>
<td><strong>ICG-R15, %</strong></td>
<td>21.0 (13.0–33.6)</td>
<td>16.0 (10.6–23.0)**</td>
<td>17.4 (11.3–28.1)</td>
</tr>
<tr>
<td><strong>Liver damage, A:B:C</strong></td>
<td>823:658:99</td>
<td>1,137:735:43**</td>
<td>1,960:1,393:142</td>
</tr>
<tr>
<td><strong>Child-Pugh, A:B:C</strong></td>
<td>1,266:282:32</td>
<td>1,568:329:18*</td>
<td>2,834:611:50</td>
</tr>
<tr>
<td><strong>ALBI grade, 1:2:3</strong></td>
<td>670:834:76</td>
<td>792:1,086:37**</td>
<td>1,462:1,920:113</td>
</tr>
<tr>
<td><strong>Tumor size, cm</strong></td>
<td>2.3 (1.6–3.6)</td>
<td>2.4 (1.6–3.5)</td>
<td>2.3 (1.6–3.5)</td>
</tr>
<tr>
<td><strong>Tumor number, single:multiple</strong></td>
<td>956:624</td>
<td>1,328:587**</td>
<td>2,284:1211</td>
</tr>
<tr>
<td><strong>AFP, ng/mL, &lt;100:≥100:ND</strong></td>
<td>1,181:39:6</td>
<td>1,057:378:145</td>
<td>1,916:649:930</td>
</tr>
<tr>
<td><strong>DCP, mAU/mL, &lt;100:≥100:ND</strong></td>
<td>720:83:40</td>
<td>265:225:62</td>
<td>1,274:1,528:51</td>
</tr>
</tbody>
</table>

* p < 0.05, ** p < 0.01, comparison between Ehime and validation groups. IQR, interquartile range; HCV, hepatitis C virus; HBV, hepatitis B virus; nonBnonC, negative for both HBV and HCV; AST, aspartate amino transferase; ALT, alanine transferase; ICG-R15, indocyanine green retention rate after 15 min; ALBI grade, albumin-bilirubin grade; TNM stage, tumor node metastasis stage; LCSGJ, Liver Cancer Study Group of Japan; ND, no data; AFP, α-fetoprotein; AFP-L3, lens culinaris agglutinin A-reactive fraction of AFP; DCP, des-γ-carboxy prothrombin; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; TACE, transcatheter arterial chemoembolization. a Median (IQR).

### Table 3. Comparison of patient distribution between liver damage, Child-Pugh, and ALBI grade

<table>
<thead>
<tr>
<th></th>
<th>Ehime group (n = 1,580)</th>
<th>Validation group (n = 1,915)</th>
<th>Total (n = 3,495)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LD A</strong></td>
<td>557</td>
<td>719</td>
<td>0</td>
</tr>
<tr>
<td><strong>LD B</strong></td>
<td>266</td>
<td>417</td>
<td>24</td>
</tr>
<tr>
<td><strong>LD C</strong></td>
<td>0</td>
<td>1</td>
<td>19</td>
</tr>
<tr>
<td><strong>CP A</strong></td>
<td>822</td>
<td>1,131</td>
<td>2</td>
</tr>
<tr>
<td><strong>CP B</strong></td>
<td>1</td>
<td>6</td>
<td>293</td>
</tr>
<tr>
<td><strong>CP C</strong></td>
<td>0</td>
<td>0</td>
<td>7</td>
</tr>
<tr>
<td><strong>ALBI-1</strong></td>
<td>664</td>
<td>785</td>
<td>0</td>
</tr>
<tr>
<td><strong>ALBI-2</strong></td>
<td>602</td>
<td>783</td>
<td>6</td>
</tr>
<tr>
<td><strong>ALBI-3</strong></td>
<td>0</td>
<td>25</td>
<td>12</td>
</tr>
</tbody>
</table>

LD, liver damage; CP, Child-Pugh; ALBI, albumin-bilirubin grade.
2,189, 579, 262, 209, and 47, respectively, and using ALBI grade were 2,157, 565, 258, 201, and 105, respectively (Fig. 1).

Prognosis for each grade according to each hepatic function assessment method was also examined (Fig. 2a–c). The value obtained with the AIC for prognosis by ALBI grade was lower as compared to the liver damage and Child-Pugh values (22,291.8, 22,379.6, and 22,392.1, respectively). Similarly, that for prognosis according to ALBI-T score was lower than those according to modified JIS and JIS scores (21,989.4, 22,076.0, and 22,075.1, respectively) (Fig. 2d–f).

The distribution of levels of ICG-R15 in each assessment is shown in Figure 3. Those of ICG-R15 <10%, 10 to <20%, 20 to <30%, and ≥30% for liver damage class A and B were similar to those for ALBI grade 1 and 2 (Fig. 3). ALBI score showed a good relationship with ICG-R15 (r = 0.616, p < 0.001) (Fig. 4a). The cutoff values for ALBI score obtained by calculating ROC and AUC values for prediction of ICG-R15 (<10%) were -2.623 and 0.798, respectively, while those for ICG-R15 (<20%) were -2.470 and 0.791, respectively, and for ICG-R15 (<30%) were -2.222 and 0.843, respectively (Fig. 4b–d).
Fig. 2. a Overall survival rates of patients according to liver damage classification (Akaike information criterion, AIC: 22,379.6). b Overall survival rates of patients according to the Child-Pugh classification (AIC: 22,392.1). c Overall survival rates of patients according to albumin-bilirubin (ALBI) grade (AIC: 22,291.8). d Overall survival rates of patients according to modified Japan Integrated scoring system (JIS) score (AIC: 22,076.0). e Overall survival rates of patients according to JIS score (AIC: 22,075.1). f Overall survival rates of patients according to ALBI-tumor node metastasis (ALBI-T) score (AIC: 21,989.4).
Discussion

Therapy for HCC in Japanese patients is generally performed according to the HCC treatment algorithm described in the “guidelines for liver cancer treatment based on scientific evidence” using the liver damage classification in the evidence-based JSH guideline [2, 3]. The liver damage classification, which requires ICG test results, has been reported to be more effective for evaluation of hepatic function than the Child-Pugh classification [26, 27]. On the other hand, the Child-Pugh classification may also be used in the evidence-based JSH guideline for consideration of nonsurgical treatment [3]. In fact, the ICG test was performed only in 46.2% of the present patients with HCC in all institutions. In addition, there are issues related to bolus injection of ICG, needed for an ICG test, and allergy to ICG, and constitutional ICG excretory defect [28] and the possibility of underestimation of hepatic function for patients who have a progressed portal-venous shunt [29] have been reported. Moreover, there might also be problems when liver damage and Child-Pugh, which has been reported to be inferior to liver damage [8], are used together in the evidence-based JSH guideline. The newly proposed ALBI grade [9] was shown to provide a better estimation of hepatic function than the Child-Pugh classification [13], and can be calculated with only albumin and total bilirubin data. Indeed, no need for imaging assessment of ascites, encephalopathy, subjective evaluation, or ICG-R15 is thought to be an advantage of ALBI grade as compared with the other classifications. In the present analysis, when ALBI grade was used for assessment of hepatic function in the Japanese HCC treatment algorithm, the distribution of patients in each therapeutic option arm was similar as compared to the liver damage classification.

No comparisons between the liver damage classification and ALBI grade have previously been made. In the present study, the Ehime and validation groups showed a similar tendency for predicting liver damage class A between ALBI grade and the Child-Pugh classification, and
the positive likelihood ratio of ALBI grade 1 for liver damage class A was good. However, as compared to the Child-Pugh classification, the frequency of patients categorized as requiring transplantation or supportive care due to decompensated classification (arm 5) was increased in the order of ALBI grade and liver damage. Child-Pugh classification had a tendency to overestimate, while liver damage had a tendency to underestimate hepatic function. In a comparison of AIC for prognosis assessment, ALBI grade and ALBI-T score were better than the others. These results suggest that ALBI grade has a superior ability for assessment of hepatic function in patients with HCC.

Surgical resection plays a very important role for improving the prognosis of HCC patients, especially in those with a low number of small-sized tumors (e.g., Milan criteria [30]). Bennett and Blumgart [31] reported that ICG-R15 was unnecessary for deciding on the indication for resection or selection of surgery. However, the ICG test has been described in many reports

![Fig. 4.](https://www.karger.com/doi/fig/10.1159/000452846)

**Fig. 4.** a Relationship between albumin-bilirubin (ALBI) score and indocyanine green retention rate at 15 min (ICG-R15) ($r = 0.616, p < 0.001$). b The cutoff value of ALBI score for predicting ICG-R15 (<10%) by calculating receiver operating characteristic (ROC) was −2.623 (sensitivity: 0.780, specificity 0.699, AUC: 0.798). c The cutoff value of ALBI score for predicting ICG-R15 (<20%) by ROC was −2.470 (sensitivity: 0.699, specificity 0.729, AUC: 0.791). d The cutoff value of ALBI score for predicting ICG-R15 (<30%) by ROC was −2.222 (sensitivity: 0.823, specificity 0.708, AUC: 0.843).
as an important examination in patients treated with surgical resection. Makuuchi and colleagues noted the efficacy of ICG test results for decision making in regard to resectable area and proposed the Makuuchi criteria [6, 32], while Torzilli et al. [33] reported satisfactory results following hepatic resection, with a 30-day postoperative mortality of 0% when the criteria were considered for selecting patients to undergo surgery. Ariizumi et al. [34] also reported that the rates of postoperative liver failure and mortality were higher in patients with ICG-R15 (10% or higher) compared to others who underwent a right hepatectomy or trisectinectomy for HCC (23 vs. 2%, \( p = 0.002 \), and 11 vs. 0%, \( p = 0.016 \), respectively)

In addition to the ICG test, development of intraoperative ultrasonically guided subsegmentectomy techniques [35, 36] has made surgical resection safer [37]. In a follow-up survey conducted in Japan (\( n = 54,145 \)), hospital mortality after a resection procedure was reported to be 2.6% [38]. When evaluation for hepatic function was done using ALBI grade, most patients with ALBI grade 1 showed an ICG-R15 value lower than 30%. The Makuuchi criteria define resectable segments according to ICG-R15 level (\(<10% = > 2 \text{ segments}, 10 \text{ to } <20% = 1 \text{ segment}, 20 \text{ to } <30% = \text{ subsegment}, 30 \text{ to } <40% = \text{ partial}, \geq 40% = \text{ enucleation} \) [6, 32]. In the present study, the distribution of ICG-R15 levels in ALBI grade 1 was similar to that in liver damage class A. Based on this result, we consider that the ICG test can be used if necessary, depending on the area scheduled for hepatectomy (e.g., subsegmental, segmental, lobectomy) in patients graded as ALBI-1, and when hepatectomy is considered for patients graded as ALBI-2. Thus, ALBI grade might help to solve difficulties associated with performing the ICG test in HCC patients and the inferiority of assessment with the Child-Pugh classification for hepatic function.

The present study has some limitations, including its retrospective nature. Further investigations with greater numbers of cases are needed to confirm our findings. The majority of the present cohort was considered for resection or RFA, and additional patients with liver damage class C should be analyzed. Of course, each parameter is only one of many indicators available for estimation of hepatic function, and a group of patients cannot be clearly divided into different therapeutic strategies using only a single parameter. Nevertheless, our findings indicate that ALBI grade is a simple but informative clinical indicator for planning treatment against HCC and is considered as adequate for use in the HCC algorithm.

**Disclosure Statement**

None of the authors has financial conflicts of interest to disclose concerning this study.

**References**


